false
0001267602
0001267602
2024-08-06
2024-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 6, 2024
ALIMERA SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-34703
|
|
20-0028718
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
6310 Town Square, Suite 400
Alpharetta, Georgia
|
|
30005
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (678) 990-5740
Not Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value per share
|
ALIM
|
The Nasdaq Stock Market LLC
(Nasdaq Global Market)
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition.
On August 6, 2024, Alimera issued a press release regarding its results of operations and financial condition for the three and six months ended June 30, 2024 as well as recent corporate highlights. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information in Item 2.02 of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:
Exhibit No.
|
|
Description
|
99.1
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ALIMERA SCIENCES, INC.
|
|
|
Dated: August 6, 2024
|
By:
|
/s/ Elliot Maltz
|
|
Name:
|
Elliot Maltz
|
|
Title:
|
Chief Financial Officer
|
Exhibit 99.1
![alimlogo1.jpg](https://www.sec.gov/Archives/edgar/data/1267602/000143774924024738/alimlogo1.jpg)
FOR IMMEDIATE RELEASE
Alimera Sciences Reports Second Quarter 2024 Results
|
●
|
Net Revenue up 54% to $27 Million vs. Q2 2023
|
|
●
|
Global End User Demand Up 6% vs. Q2 2023
|
|
●
|
Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals Inc.
|
ATLANTA, August 6, 2024 -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. (“ANI”).
“We are pleased with our strong second quarter results, in line with our expectations, as we completed the integration of YUTIQ into our U.S. business and delivered $50 million in revenue in the first half this year," said Rick Eiswirth, Alimera’s President and Chief Executive Officer. "Further, we believe the acquisition agreement entered into with ANI Pharmaceuticals late in the second quarter is a testament to the value we have created at Alimera, and we look forward to completing the transaction later this quarter."
Key Second Quarter Financial Highlights:
|
●
|
Net revenue of $27.0 million up 54% vs Q2 2023
|
|
●
|
Net loss improved to $(3.3) million vs. $(10.7) million in Q2 2023
|
|
●
|
Adjusted EBITDA of $6.7 million vs. $0.9 million in Q2 2023
|
|
●
|
U.S. net revenue of $17.6 million, up 48% vs.$11.9 million in Q2 2023
|
|
●
|
International net revenue of $9.4 million, up 65% vs. $5.7 million in Q2 2023
|
|
●
|
Global end user demand of 3,821 up 6% vs. Q2 2023 on a pro-forma basis
|
Second Quarter Corporate Highlights:
|
●
|
On June 21, 2024, Alimera entered into an agreement and plan of merger with ANI. Under the proposed merger, Alimera will be acquired for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. The transaction, which values Alimera’s equity at approximately $320 million in up front consideration, was approved by the ANI and Alimera Boards of Directors and is expected to close later this year. For more information, visit ANI’s website www.anipharmaceuticals.com
|
|
●
|
Modified the terms associated with royalty payments Alimera is obligated to pay SWK Funding LLC (“SWK”), reducing the royalty to 3.125% of net revenues, and defining any product containing fluocinolone acetonide (“FAc”) as being subject to such royalty, including ILUVIEN and YUTIQ.
|
Second Quarter 2024 Financial Results
Net Revenue
Consolidated global net revenue was up 54% to approximately $27 million for Q2 2024, compared to $17.5 million for Q2 2023, driven by the addition of YUTIQ in the U.S. segment, as well as increased sales volumes in the International segment of the business.
U.S. net revenue increased 48% to approximately $17.6 million for Q2 2024 compared to U.S. net revenue of $11.9 million for Q2 2023. The increase was primarily driven by net revenue from YUTIQ, which Alimera acquired in May 2023. U.S. end user demand grew by 6% in Q2 2024 to 2,189 units vs Q2 2023 on a pro-forma basis.
International net revenue increased 65% to approximately $9.4 million in Q2 2024, compared to approximately $5.7 million in Q2 2023. The increase in international net revenue in Q2 2024 was driven both by increased stocking of our international distributors and growth in end user demand. International end user demand grew 6% in Q2 2024 to 1,632 units vs Q2 2023.
Operating Expenses
Total operating expenses were approximately $23.2 million for Q2 2024, compared to approximately $16.3 million for Q2 2023. The increase was primarily attributable to $2.2 million in general and administrative expenses related to the merger agreement with ANI Pharmaceuticals Inc., $1.8 million of additional sales and marketing expenses driven by expansion of our commercial infrastructure to support selling two products in the U.S., $1.2 million in additional amortization expense attributable to the YUTIQ acquisition in May 2023, and $1.2 million in additional stock-based compensation expense.
Cash and Cash Equivalents
As of June 30, 2024, Alimera had cash and cash equivalents of approximately $10.8 million, compared to $14.3 million at March 31, 2024 and $12.1 million at December 31, 2023. During the second quarter of 2024, the Company made $1.9 million of accrued licensor payments to EyePoint Pharmaceuticals, Inc. related to the acquisition of YUTIQ in May 2023, and $2.4 million of accrued exit fee payments as required by the Company’s existing loan agreements with SLR Capital Partners, LLC due to the achievement of certain revenue milestones.
About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.
Non-GAAP Financial Measures
This press release presents Adjusted EBITDA, as defined below, which is a non-GAAP financial measure. Alimera uses this measure to supplement the financial information presented on a GAAP basis. Alimera believes that excluding certain items from its GAAP financial results allows management to better understand its ongoing operations and analyze its financial performance from period to period and provides meaningful supplemental information to its investors.
Alimera defines “Adjusted EBITDA” as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains and losses from foreign currency exchange transactions, gains on extinguishment of debt, preferred stock dividends, severance expenses, expenses incurred with Merger Agreement, and change in fair value of warrant asset.
Alimera believes that Adjusted EBITDA, when taken together with its corresponding GAAP financial measure, provides meaningful supplemental information to its investors regarding its performance by excluding certain items that may not be indicative of its business, results of operations, or outlook. Accordingly, Adjusted EBITDA for the three months ended June 30, 2024 and 2023, together with a reconciliation to GAAP net income or loss, its most directly comparable GAAP financial measure, has been presented in the table entitled “Reconciliation of GAAP Loss to Non-GAAP Adjusted EBITDA.”
This non-GAAP financial measure may not be comparable to similarly titled measures reported by other companies, including companies in Alimera’s industry, because not all companies calculate Adjusted EBITDA in an identical manner or may use other financial measures to evaluate their performance. Therefore, this non-GAAP financial measure may be limited in usefulness for comparison between companies.
The presentation of this non-GAAP financial measure is not intended to be considered in isolation from or as a substitute for other financial performance measures prepared in accordance with GAAP and should be read only in conjunction with financial information presented on a GAAP basis. The principal limitation of this non-GAAP financial measure is that it excludes significant elements required by GAAP to be recorded in Alimera’s financial statements. In addition, this non-GAAP financial measure is subject to inherent limitations because it reflects the exercise of judgments by management. Investors are encouraged not to rely on any single financial measure to evaluate Alimera’s business.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, Alimera’s expectations with respect to growth opportunities, demand for its product, its business strategy, future operations, future financial position including the timeline for achieving positive Adjusted EBITDA, future revenues, projected costs, prospects, plans and objectives. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “contemplates,” “predict,” “project,” “target,” “likely,” “potential,” “continue,” “ongoing,” “will,” “would,” “should,” “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based on current expectations and involve inherent risks and uncertainties (some of which are beyond Alimera’s control), including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s most recently filed Annual Report on Form 10-K, most recently filed Quarterly Report on Form 10-Q, and any of Alimera’s subsequent filings with the U.S. Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely on the forward-looking statements Alimera makes or that are made on its behalf as predictions of future events. These forward-looking statements speak only as of the date of this press release. Alimera undertakes no obligation to publicly update or revise any of the forward-looking statements made in this press release, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Additional Information and Where to Find It
In connection with the Merger, Alimera intends to file a preliminary and definitive proxy statement. The definitive proxy statement and proxy card will be delivered to Alimera’s stockholders in advance of the special meeting relating to the proposed acquisition. Each of ANI and Alimera also plan to file other relevant materials with the SEC in connection with the Merger. INVESTORS IN AND SECURITY HOLDERS OF ALIMERA ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE, AS WELL AS ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR FURNISHED OR WILL BE FILED OR WILL BE FURNISHED BY EACH OF ANI AND ALIMERA WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE MERGER, RELATED MATTERS AND THE PARTIES TO THE MERGER. Materials filed by ANI and Alimera can be obtained free of charge at the SEC’s website, www.sec.gov. In addition, materials filed by ANI can be obtained free of charge at ANI’s website, www.anipharmaceuticals.com, and materials filed by Alimera can be obtained free of charge at Alimera’s website, www.alimerasciences.com.
For investor inquiries: |
For media inquiries: |
Scott Gordon |
Jules Abraham |
for Alimera Sciences |
for Alimera Sciences |
scottg@coreir.com |
julesa@coreir.com |
# # #
ALIMERA SCIENCES, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2024
|
|
|
2023
|
|
|
|
(In thousands, except share and per share data)
|
|
Assets
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
10,828 |
|
|
$ |
12,058 |
|
Restricted cash
|
|
|
33 |
|
|
|
32 |
|
Accounts receivable, net
|
|
|
37,079 |
|
|
|
34,545 |
|
Prepaid expenses and other current assets
|
|
|
4,013 |
|
|
|
3,909 |
|
Inventory
|
|
|
3,455 |
|
|
|
1,879 |
|
Total current assets
|
|
|
55,408 |
|
|
|
52,423 |
|
Property and equipment, net
|
|
|
2,278 |
|
|
|
2,466 |
|
Right-of-use assets, net
|
|
|
996 |
|
|
|
1,124 |
|
Intangible assets, net
|
|
|
91,587 |
|
|
|
97,355 |
|
Deferred tax asset
|
|
|
101 |
|
|
|
104 |
|
Warrant asset
|
|
|
7 |
|
|
|
52 |
|
Total assets
|
|
$ |
150,377 |
|
|
$ |
153,524 |
|
Liabilities and Stockholders’ Equity
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$ |
10,208 |
|
|
$ |
8,252 |
|
Accrued expenses
|
|
|
5,708 |
|
|
|
6,192 |
|
Accrued licensor payment
|
|
|
3,677 |
|
|
|
7,275 |
|
Finance lease obligations
|
|
|
245 |
|
|
|
194 |
|
Total current liabilities
|
|
|
19,838 |
|
|
|
21,913 |
|
Non-current liabilities:
|
|
|
|
|
|
|
|
|
Notes payable, net of discount
|
|
|
69,731 |
|
|
|
64,489 |
|
Accrued licensor payments
|
|
|
16,111 |
|
|
|
15,136 |
|
Other non-current liabilities
|
|
|
5,909 |
|
|
|
5,816 |
|
Total liabilities
|
|
|
111,589 |
|
|
|
107,354 |
|
Commitments and contingencies (note 8)
|
|
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $.01 par value — 10,000,000 shares authorized at June 30, 2024 and December 31, 2023, none issued
|
|
|
— |
|
|
|
— |
|
Common stock, $.01 par value — 150,000,000 shares authorized, 52,387,763 shares issued and outstanding at June 30, 2024 and 52,354,450 shares issued and outstanding at December 31, 2023
|
|
|
524 |
|
|
|
524 |
|
Common stock warrants
|
|
|
4,396 |
|
|
|
4,396 |
|
Additional paid-in capital
|
|
|
464,825 |
|
|
|
462,446 |
|
Accumulated deficit
|
|
|
(428,052 |
) |
|
|
(418,490 |
) |
Accumulated other comprehensive loss
|
|
|
(2,905 |
) |
|
|
(2,706 |
) |
Total stockholders’ equity
|
|
|
38,788 |
|
|
|
46,170 |
|
Total liabilities and stockholders’ equity
|
|
$ |
150,377 |
|
|
$ |
153,524 |
|
ALIMERA SCIENCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 30,
|
|
|
June 30,
|
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
|
|
(In thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
$ |
27,000 |
|
|
$ |
17,538 |
|
|
$ |
50,011 |
|
|
$ |
31,084 |
|
Cost of goods sold, excluding depreciation and amortization
|
|
|
(3,831 |
) |
|
|
(2,425 |
) |
|
|
(7,184 |
) |
|
|
(4,453 |
) |
Gross profit
|
|
|
23,169 |
|
|
|
15,113 |
|
|
|
42,827 |
|
|
|
26,631 |
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research, development and medical affairs expenses
|
|
|
4,263 |
|
|
|
3,648 |
|
|
|
8,624 |
|
|
|
7,812 |
|
General and administrative expenses
|
|
|
7,379 |
|
|
|
4,373 |
|
|
|
12,811 |
|
|
|
8,544 |
|
Sales and marketing expenses
|
|
|
8,511 |
|
|
|
6,434 |
|
|
|
17,593 |
|
|
|
12,238 |
|
Depreciation and amortization
|
|
|
3,093 |
|
|
|
1,866 |
|
|
|
6,178 |
|
|
|
2,547 |
|
Total operating expenses
|
|
|
23,246 |
|
|
|
16,321 |
|
|
|
45,206 |
|
|
|
31,141 |
|
Loss from operations
|
|
|
(77 |
) |
|
|
(1,208 |
) |
|
|
(2,379 |
) |
|
|
(4,510 |
) |
Interest expense and other, net
|
|
|
(3,153 |
) |
|
|
(1,694 |
) |
|
|
(6,892 |
) |
|
|
(3,361 |
) |
Unrealized foreign currency loss, net
|
|
|
(125 |
) |
|
|
(7 |
) |
|
|
(321 |
) |
|
|
(20 |
) |
Loss on extinguishment of debt
|
|
|
— |
|
|
|
(1,079 |
) |
|
|
— |
|
|
|
(1,079 |
) |
Change in fair value of common stock warrant
|
|
|
— |
|
|
|
(105 |
) |
|
|
— |
|
|
|
(91 |
) |
Change in fair value of warrant asset
|
|
|
1 |
|
|
|
(5,911 |
) |
|
|
(45 |
) |
|
|
(5,911 |
) |
Net loss before income taxes
|
|
|
(3,354 |
) |
|
|
(10,004 |
) |
|
|
(9,637 |
) |
|
|
(14,972 |
) |
Income tax benefit (provision)
|
|
|
43 |
|
|
|
(25 |
) |
|
|
75 |
|
|
|
(25 |
) |
Net loss
|
|
|
(3,311 |
) |
|
|
(10,029 |
) |
|
|
(9,562 |
) |
|
|
(14,997 |
) |
Preferred stock dividends
|
|
|
— |
|
|
|
(669 |
) |
|
|
— |
|
|
|
(683 |
) |
Net loss applicable to common stockholders
|
|
$ |
(3,311 |
) |
|
$ |
(10,698 |
) |
|
$ |
(9,562 |
) |
|
$ |
(15,680 |
) |
Net loss per share — basic and diluted
|
|
$ |
(0.06 |
) |
|
$ |
(1.32 |
) |
|
$ |
(0.18 |
) |
|
$ |
(2.07 |
) |
Weighted average shares outstanding — basic and diluted
|
|
|
54,383,604 |
|
|
|
8,093,640 |
|
|
|
54,370,216 |
|
|
|
7,565,868 |
|
RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA
(UNAUDITED)
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 30,
|
|
|
June 30,
|
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
|
|
(In thousands)
|
|
U.S. GAAP net loss
|
|
$ |
(3,311 |
) |
|
$ |
(10,029 |
) |
|
$ |
(9,562 |
) |
|
$ |
(14,997 |
) |
Adjustments to U.S. GAAP net loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense and other, net
|
|
|
3,153 |
|
|
|
1,694 |
|
|
|
6,892 |
|
|
|
3,361 |
|
Expenses incurred with Merger Agreement
|
|
|
2,226 |
|
|
|
— |
|
|
|
2,226 |
|
|
|
— |
|
Income tax (benefit) provision
|
|
|
(43 |
) |
|
|
25 |
|
|
|
(75 |
) |
|
|
25 |
|
Depreciation and amortization
|
|
|
3,093 |
|
|
|
1,866 |
|
|
|
6,178 |
|
|
|
2,547 |
|
Stock-based compensation
|
|
|
1,457 |
|
|
|
217 |
|
|
|
2,302 |
|
|
|
442 |
|
Foreign currency exchange losses
|
|
|
125 |
|
|
|
7 |
|
|
|
321 |
|
|
|
20 |
|
Extinguishment of debt
|
|
|
— |
|
|
|
1,079 |
|
|
|
— |
|
|
|
1,079 |
|
Change in fair value of warrant asset
|
|
|
(1 |
) |
|
|
5,911 |
|
|
|
45 |
|
|
|
5,911 |
|
Change in fair value of common stock warrant
|
|
|
— |
|
|
|
105 |
|
|
|
— |
|
|
|
91 |
|
Severance expenses
|
|
|
15 |
|
|
|
— |
|
|
|
191 |
|
|
|
— |
|
Non-GAAP adjusted EBITDA
|
|
$ |
6,714 |
|
|
$ |
875 |
|
|
$ |
8,518 |
|
|
$ |
(1,521 |
) |
v3.24.2.u1
Document And Entity Information
|
Aug. 06, 2024 |
Document Information [Line Items] |
|
Entity, Registrant Name |
ALIMERA SCIENCES, INC.
|
Document, Type |
8-K
|
Document, Period End Date |
Aug. 06, 2024
|
Entity, Incorporation, State or Country Code |
DE
|
Entity, File Number |
001-34703
|
Entity, Tax Identification Number |
20-0028718
|
Entity, Address, Address Line One |
6310 Town Square
|
Entity, Address, Address Line Two |
Suite 400
|
Entity, Address, City or Town |
Alpharetta
|
Entity, Address, State or Province |
GA
|
Entity, Address, Postal Zip Code |
30005
|
City Area Code |
678
|
Local Phone Number |
990-5740
|
Written Communications |
true
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.01 par value per share
|
Trading Symbol |
ALIM
|
Security Exchange Name |
NASDAQ
|
Entity, Emerging Growth Company |
false
|
Amendment Flag |
false
|
Entity, Central Index Key |
0001267602
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Alimera Sciences (NASDAQ:ALIM)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Alimera Sciences (NASDAQ:ALIM)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024